U.S. Supreme Court Sides With Teva in Drug Dispute

Judges rule that a federal appeals court wrongly overturned five of Teva's patents for the drug Copaxone.

Teva's headquarters in Jerusalem.
Bloomberg

The U.S. Supreme Court has sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

The justices ruled Tuesday that a federal appeals court wrongly overturned five of Teva's patents for the drug Copaxone. The decision allows the Israel-based company to keep its exclusive rights to the drug until September 2015.

Copaxone generates about $4 billion in annual sales for Teva.

Teva had argued that the U.S. Court of Appeals for the Federal Circuit should not have second-guessed factual findings made by a federal district court that had earlier ruled in Teva's favor.

The justices agreed that the Federal Circuit should have deferred to factual findings made by the lower court.